Dong-A ST
As of the edition of 20 October 2026, Dong-A ST runs 58 drugs, 2 of them marketed; it is on route A at 2 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 15 |
| Went quiet | 15 |
| Stopped | 1 |
| Status not established | 25 |
| Total | 58 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Evogliptin | none listed | 1 |
| Acetylcarnitine | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 2 targets, route B at 1 target.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Dong-A ST needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Hormones: 17 trials led
- Nutrition and metabolism: 15 trials led
- Digestive system: 8 trials led